- One of Victory Square Technologies portfolio company’s has been granted approval by The Brazilian Health Regulatory Agency to begin distributing its COVID-19 Rapid Tests
- Victory Square Health received approval for its Safetest 15 Minute Covid-19 Rapid Test
- These tests have a 96.6 per cent sensitivity and can confirm whether a person is currently infected with the COVID-19 virus or whether they were previously infected and unaware of it
- Victory Square Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions
- Victory Square Technologies is up 13.33 per cent to C$0.68 per share
A Victory Square Technologies’ (VST) portfolio company has been approved by The Brazilian Health Regulatory Agency to begin distributing its COVID-19 rapid tests.
Its portfolio company, Victory Square Health received approval for the Safetest 15 Minute Covid-19™ Rapid Test. These tests have a 96.6 per cent sensitivity and can confirm whether a person is currently infected with the COVID-19 virus or whether they were previously infected and unaware of it.
Victory Square Health CEO Felipe Peixoto said since the company’s three hour Elisa COVID-19 lab tests were approved by The Brazilian Health Regulatory Agency in September, the country has seen an increase of approximately 3.5 million COVID cases.
“This approval from Brazil now enables our company to strategically produce and sell our cost-effective and highly accurate Rapid Test products to the world’s third largest Covid-19 infection rate country,” Peixoto said.
Victory Square Health was founded in 2016 to accelerate the development of personalized medicine and technology solutions including diagnostic tests to support patient’s care and improve health outcomes.
Victory Square Technologies is up 13.33 per cent to C$0.68 per share at 2:33 pm EST.
